Global Pharmacogene Testing Market Strategic Research Report

Scope of the Report

The global Pharmacogene Testing market size is predicted to grow from US$ 726 million in 2025 to US$ 1,422 million in 2032; it is expected to grow at a CAGR of 10.2% from 2026 to 2032.

Pharmacogene Testing is a precision medicine technology that uses molecular biology techniques to analyze gene sequence variations in individuals related to drug metabolism, efficacy, and safety. It predicts the absorption, distribution, metabolism, and excretion (ADME) processes of drugs in the body, as well as therapeutic responses and adverse reaction risks, providing a scientific basis for the development of personalized clinical medication regimens.

Technological innovation is the core driving force behind market development. On the one hand, mainstream technologies are constantly being optimized. High-throughput sequencing (NGS) is deeply integrated with technologies such as multiplex PCR and microarray chips, which not only improves detection throughput and accuracy but also significantly reduces costs. On the other hand, new technologies are gradually being implemented. Breakthroughs in CRISPR gene editing technology and AAV delivery systems have promoted the popularization of personalized treatment plans. Nanopore sequencing technology has shortened the tumor mutation burden detection cycle to 8 hours, and CRISPR-Cas9-assisted targeted enrichment technology has reduced the DNA input requirements, adapting to more clinical sample scenarios. In addition, the integration of AI technology and gene data analysis has become a new direction, enabling in-depth mining of data on the correlation between genes and drug phenotypes, improving the efficiency and accuracy of clinical interpretation of test reports.

This report presents a comprehensive overview of the global Pharmacogene Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Heart Disease Testing
• Gastrointestinal Disease Testing
• Infectious Disease Testing
• Others

Segment by Technology

• PCR Technology
• NGS Technology
• Gene Chip Technology
• Others

Segment by Sample

• Blood Sample
• Tissue Sample
• Saliva Sample
• Others

Segment by players, this report covers

• Australian Clinical Labs
• MyHeritage
• LabCorp
• Myriad Genetics
• Gravity Diagnostics
• Quest Diagnostics
• Gene By Gene（myDNA Inc.）
• DNA Diagnostics Center
• Sanford Imagenetics
• Ambry Genetics
• Living DNA
• EasyDNA
• Pathway Genomics
• Centrillion Technology
• Color Genomics
• Anglia DNA Services
• African Ancestry
• Canadian DNA Services
• DNA Family Check
• Alpha Biolaboratories
• Test Me DNA
• 23 Mofang
• Genetic Health
• DNA Services of America
• Shuwen Biotech
• Mapmygenome
• Full Genomes

Segment by Application

• Clinical Treatment
• Drug Development
• Health Management
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pharmacogene Testing market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Clinical Treatment, Drug Development, Health Management evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact